<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03994822</url>
  </required_header>
  <id_info>
    <org_study_id>pCT-001-19</org_study_id>
    <nct_id>NCT03994822</nct_id>
  </id_info>
  <brief_title>pRESET for Occlusive Stroke Treatment</brief_title>
  <acronym>PROST</acronym>
  <official_title>pRESET for Occlusive Stroke Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>phenox Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>phenox Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Compare the safety and effectiveness of pRESET to Solitaire in the treatment of stroke&#xD;
      related to large vessel occlusion&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To determine the safety and effectiveness of pRESET for the treatment of acute ischemic&#xD;
      stroke within 8 hours of symptom onset (defined as time patient was last seen well) due to&#xD;
      large vessel occlusion and to compare safety and effectiveness to the predicate device,&#xD;
      Solitaire™ Platinum revascularization device&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 4, 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective, multi-center randomized</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>The blinded assessor performs all study assessments during and after hospital discharge (i.e., 24 hours, Day 7/Discharge (whichever is earlier), and 30 and day 90 visits</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Effectiveness Endpoint: Patients with a Modified Rankin Scale (mRS) &lt;/= 2</measure>
    <time_frame>90 (+/-15) days</time_frame>
    <description>Global disability assessed via the blinded evaluation of the proportion of patients with a Modified Rankin Scale (mRS) &lt;/= 2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Safety Endpoint: Device- or procedure-related symptomatic intracerebral hemorrhage (sICH)</measure>
    <time_frame>24 (-8/+12) hours</time_frame>
    <description>Proportion of subjects with device- or procedure-related symptomatic intracerebral hemorrhage (sICH)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Successful Revascularization measured using the expanded Thrombolysis in Cerebrovascular Infarction (eTICI)</measure>
    <time_frame>During Index Procedure</time_frame>
    <description>Proportion of subjects with eTICI 2b50 or greater flow in the target vessel post procedure with 3 or fewer passes of the assigned study device.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Successful Revascularization on first pass measured using the expanded Thrombolysis in Cerebrovascular Infarction (eTICI)</measure>
    <time_frame>During Index Procedure</time_frame>
    <description>Proportion of patients with eTICI 2c or greater, following the first pass of the assigned study device</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall mortality following the index stroke</measure>
    <time_frame>90 (+/-15) days</time_frame>
    <description>Overall mortality following the index stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of mRS shift across the entire spectrum of disability</measure>
    <time_frame>90 (+/-15) days</time_frame>
    <description>Distribution of mRS shift across the entire spectrum of disability</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">316</enrollment>
  <condition>Brain Diseases</condition>
  <condition>Cardiovascular Diseases</condition>
  <condition>Central Nervous System Diseases</condition>
  <condition>Cerebrovascular Disorders</condition>
  <condition>Ischemia</condition>
  <condition>Nervous System Diseases</condition>
  <condition>Pathologic Processes</condition>
  <condition>Stroke, Ischemic</condition>
  <condition>Stroke, Acute</condition>
  <condition>Vascular Diseases</condition>
  <arm_group>
    <arm_group_label>pRESET Thrombectomy Device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mechanical Thrombectomy using the pRESET Thrombectomy Device</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Solitaire Revascularization Device</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mechanical Thrombectomy using the Solitaire Revascularization Device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Mechanical Thrombectomy using the pRESET Thrombectomy device</intervention_name>
    <description>Clot removal using the pRESET Thrombectomy device</description>
    <arm_group_label>pRESET Thrombectomy Device</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Mechanical Thrombectomy using the Solitaire Revascularization Device</intervention_name>
    <description>Clot removal using the Solitaire Revascularization Device</description>
    <arm_group_label>Solitaire Revascularization Device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age &gt;/=18&#xD;
&#xD;
          2. Clinical signs consistent with acute ischemic stroke&#xD;
&#xD;
          3. Subject is able to be treated within 8 hours of stroke symptom onset and within 1.5&#xD;
             hours (90 min) from screening CT / MRI to groin puncture.&#xD;
&#xD;
          4. Pre-stroke modified Rankin Score of 0 or 1&#xD;
&#xD;
          5. NIHSS ≥6 at the time of enrolment&#xD;
&#xD;
          6. If tPA is indicated, initiation of IV tPA should be administered as soon as possible&#xD;
             and no later than 3.0 hours of onset of stroke symptoms (onset time is defined as the&#xD;
             last time when the patient was witnessed to be at baseline neurologic status), with&#xD;
             investigator verification that the subject has received/is receiving the correct IV&#xD;
             tPA dose (0.9mg/kg) for the estimated weight.&#xD;
&#xD;
          7. Expanded Thrombolysis in Cerebral Infarction (eTICI) 0-1 flow confirmed by angiography&#xD;
             that is accessible to the mechanical thrombectomy device in the following locations:&#xD;
&#xD;
               1. Intracranial internal carotid&#xD;
&#xD;
               2. M1 and/or M2 segment of the MCA&#xD;
&#xD;
               3. Carotid terminus&#xD;
&#xD;
               4. Vertebral artery&#xD;
&#xD;
               5. Basilar artery&#xD;
&#xD;
             Note: M1 segment of the MCA is defined as the arterial trunk from its origin at the&#xD;
             ICA to the first bifurcation or trifurcation into major branches neglecting the small&#xD;
             temporo-polar branch.&#xD;
&#xD;
          8. Imaging scores as follows:&#xD;
&#xD;
             · ASPECTS score must be 6-10 on NCCT or DWI-MRI.&#xD;
&#xD;
             If automated core volume assessment software is used:&#xD;
&#xD;
               -  MR diffusion-weighted imaging (DWI) ≤50cc&#xD;
&#xD;
               -  Computed tomography perfusion (CTP) core ≤50 cc&#xD;
&#xD;
          9. Subject is willing to conduct protocol-required follow-up visits.&#xD;
&#xD;
         10. A valid completed informed consent by participant or LAR (Legally Authorized&#xD;
             Representative)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject who has received IA-tPA prior to enrolment in the study&#xD;
&#xD;
          2. Female who is pregnant or lactating or has a positive pregnancy test at time of&#xD;
             admission.&#xD;
&#xD;
          3. Rapid neurological improvement prior to study enrolment suggesting resolution of&#xD;
             signs/symptoms of stroke&#xD;
&#xD;
          4. Known serious sensitivity to radiographic contrast agents&#xD;
&#xD;
          5. Known sensitivity to nickel, titanium metals, or their alloys&#xD;
&#xD;
          6. Subjects already enrolled in other investigational studies that would interfere with&#xD;
             study endpoints&#xD;
&#xD;
          7. Known hereditary or acquired hemorrhagic diathesis, coagulation factor deficiency. (A&#xD;
             subject without history or suspicion of coagulopathy does not require INR or&#xD;
             prothrombin time lab results to be available prior to enrolment.)&#xD;
&#xD;
          8. Known renal failure as defined by a serum creatinine &gt; 2.0 mg/dl (or 176.8 μmol/l) or&#xD;
             glomerular filtration rate (GFR) &lt; 30.&#xD;
&#xD;
          9. Subject who requires hemodialysis or peritoneal dialysis, or who has a&#xD;
             contraindication to an angiogram for whatever reason.&#xD;
&#xD;
         10. Life expectancy of less than 90 days&#xD;
&#xD;
         11. Clinical presentation suggests a subarachnoid hemorrhage, even if initial CT or MRI&#xD;
             scan is normal&#xD;
&#xD;
         12. Suspicion of aortic dissection&#xD;
&#xD;
         13. Subject with a comorbid disease or condition that would confound the neurological and&#xD;
             functional evaluations or compromise survival or ability to complete follow-up&#xD;
             assessments.&#xD;
&#xD;
         14. Subject is known to currently use or has a recent history of illicit drug(s) or abuses&#xD;
             alcohol (defined as regular or daily consumption of more than four alcoholic drinks&#xD;
             per day).&#xD;
&#xD;
         15. Known arterial condition (e.g., proximal vessel stenosis or pre-existing stent) that&#xD;
             would prevent the device from reaching the target vessel and/or preclude safe recovery&#xD;
             of the device&#xD;
&#xD;
         16. Subject who requires balloon angioplasty or stenting of the carotid artery at the time&#xD;
             of the index procedure&#xD;
&#xD;
         17. Angiographic evidence of carotid dissection&#xD;
&#xD;
             Imaging exclusion criteria:&#xD;
&#xD;
         18. CT or MRI evidence of hemorrhage on presentation&#xD;
&#xD;
         19. CT or MRI evidence of mass effect or intra-cranial tumor (except small meningioma)&#xD;
&#xD;
         20. CT or MRI evidence of cerebral vasculitis&#xD;
&#xD;
         21. CT or MRI-DWI showing ASPECTS 0-5. Alternatively, if automated core volume assessment&#xD;
             software is used, MRI-DWI or CTP core &gt; 50cc.&#xD;
&#xD;
         22. CT/MRI shows evidence of carotid dissection or complete cervical carotid occlusion&#xD;
             requiring a stent&#xD;
&#xD;
         23. Any imaging evidence that suggests, in the opinion of the investigator, the subject is&#xD;
             not appropriate for mechanical thrombectomy intervention (e.g. inability to navigate&#xD;
             to target lesion, moderate/large infarct with poor collateral circulation, etc.).&#xD;
&#xD;
         24. Occlusions in multiple vascular territories (e.g., bilateral anterior circulation, or&#xD;
             anterior/posterior circulation) as confirmed by angiography, or clinical evidence of&#xD;
             bilateral strokes or strokes in multiple territories&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raul G Nogueira, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Grady Memorial Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richardo A Hanel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baptist Medical Center, Jacksonville</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gary Brogan</last_name>
    <phone>+35391740103</phone>
    <email>gary.brogan@phenox.ie</email>
  </overall_contact>
  <location>
    <facility>
      <name>Providence Little Company of Mary Medical Center</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jason Tarpley, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33146</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert M Starke, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baptist Health Research Institute Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richardo A Hanel, MD</last_name>
    </contact>
    <investigator>
      <last_name>Eric Sauvageau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Grady Memorial Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diogo Haussen, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Chen, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Advocate Lutheran General Hospital</name>
      <address>
        <city>Downers Grove</city>
        <state>Illinois</state>
        <zip>60515</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Demetrius Lopes, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edgar Samaniego, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ajit Puri, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>JFK Medical Center</name>
      <address>
        <city>Edison</city>
        <state>New Jersey</state>
        <zip>08820</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jawad Kirmani, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allan Brook, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Buffalo General Medical Center</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adnan H Siddiqui, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NYU Langone Health</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eytan Raz, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Mount Sinai Hosptial</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johanna T Fifi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>OhioHealth Research Institute</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ronald F Budzik Jr, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hormozd Bozorgchami, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra Narayanan, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Württemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Markus Möhlenbruch, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar Technische Universität München</name>
      <address>
        <city>München</city>
        <state>Bavaria</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tobias Boeckh-Behrens, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Bremen-Mitte</name>
      <address>
        <city>Bremen</city>
        <state>Lower Saxony</state>
        <zip>28205</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Roth, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein, Campus Lübeck</name>
      <address>
        <city>Lübeck</city>
        <state>Schleswig-Holstein</state>
        <zip>23562</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Schramm, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Helios Klinikum Erfurt GmbH</name>
      <address>
        <city>Erfurt</city>
        <state>Thuringia</state>
        <zip>99089</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joachim Klisch, Prof.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>May 24, 2019</study_first_submitted>
  <study_first_submitted_qc>June 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2019</study_first_posted>
  <last_update_submitted>April 20, 2021</last_update_submitted>
  <last_update_submitted_qc>April 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Brain</keyword>
  <keyword>Brain Clot</keyword>
  <keyword>Brain Infarction</keyword>
  <keyword>Cerebral Ischemia</keyword>
  <keyword>Cerebrovascular Disorders</keyword>
  <keyword>Ischemia</keyword>
  <keyword>Ischemic</keyword>
  <keyword>Ischemic Stroke</keyword>
  <keyword>Mechanical Thrombectomy</keyword>
  <keyword>Neurovascular Intervention</keyword>
  <keyword>phenox</keyword>
  <keyword>pRESET</keyword>
  <keyword>pRESET Thrombectomy Device</keyword>
  <keyword>Revascularization</keyword>
  <keyword>Randomized Control</keyword>
  <keyword>Solitaire</keyword>
  <keyword>Stent Retriever</keyword>
  <keyword>Stroke</keyword>
  <keyword>Vascular Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Nervous System Diseases</mesh_term>
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Central Nervous System Diseases</mesh_term>
    <mesh_term>Cerebrovascular Disorders</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Pathologic Processes</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

